Market Overview:
The global human cytomegalovirus 65 kDa phosphoprotein market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of human cytomegalovirus infections, rising demand for effective and safe therapeutics, and growing investments in research and development. However, the high cost of treatment may restrain the growth of this market to some extent. Based on type, the global human cytomegalovirus 65 kDa phosphoprotein market is segmented into HB-101, CyMVectin, ASP-0113, PepVax and others. HB-101 is expected to account for a major share of this market during the forecast period owing to its high efficacy and safety profile. Based on application, this market is segmented into brain tumor, hematological tumor (leukemia & lymphoma), kidney transplant rejection prevention & treatment (acute renal failure), liver transplant rejection prevention & treatment (hepatic encephalopathy) and others. The brain tumor segment is projected to grow at a highest CAGR during the forecast period owing to increasing incidence rates of brain tumors across all regions worldwide.
Product Definition:
Human cytomegalovirus 65 kDa Phosphoprotein is a protein that is found in human cytomegalovirus. This protein plays a role in the virus' replication and transcription.
HB-101:
HB-101 is a human cytomegalovirus (HCMV) protein that plays an important role in the life cycle of HCMV. The virus infects the cells and uses these infected cells to produce new virus particles. HB-101 has been studied extensively as it is one of the major viral proteins that aids in viral replication and pathogenesis.
CyMVectin:
Cytomegalovirus 65 kDa phosphoprotein, also known as CyMV (65-kDa protein), is an important viral protein that helps the virus to enter host cells. It is a member of the potexavirus protease inhibitor family and functions by binding to host cell serine/threonine proteins. The virus uses this protein for its entry into host cells during infection.
Application Insights:
The global human cytomegalovirus 65 kDa phosphoprotein market is segmented by application into brain tumor, hematological tumor, kidney transplant rejection, liver transplant rejection and others. The brain tumor segment dominated the overall market in terms of revenue share in 2017 owing to the increasing prevalence of neurological disorders such as Alzheimer¢â‚¬â„¢s disease and Parkinson¢â‚¬â„¢s disease. According to data published by WHO in 2018, it has been estimated that around 60% of people above 60 years have antibodies against CMV which indicates previous infection with this virus. This factor is anticipated to fuel demand for HCMV-based therapies over the forecast period.
On the other hand, hematological tumors are expected to be one of fastest growing segments due largely avoiding use anti-CMV antibody therapy due lack awareness among patients regarding availability.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong research base and several clinical trials being conducted for cytomegalovirus-related diseases are some of the major factors contributing to its growth. In addition, increasing awareness about these viruses and their treatment options is expected to drive demand over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to an increase in cancer incidence rates coupled with growing healthcare expenditure levels in emerging countries such as China, India, South Korea & Japan (KSOJ). Moreover, favorable government initiatives pertaining towards cancer care are also expected to boost regional demand over the next six years.
Growth Factors:
- Increasing incidence of human cytomegalovirus (HCMV) infection: The increasing incidence of HCMV infection is the major growth driver for the human cytomegalovirus 65 kDa phosphoprotein market. According to a study by Centers for Disease Control and Prevention (CDC), around 1 in 150 children are born with congenital HCMV infection, which is the most common congenital viral infection in United States. Moreover, as per World Health Organization (WHO), an estimated 5%–10% of adults are infected with HCMV worldwide. Thus, rising prevalence of this virus is expected to boost demand for human cytomegalovirus 65 kDa phosphoprotein over the forecast period.
- Growing awareness about benefits offered by human cytomegalovirus 65 kDa phosphoprotein: There is growing awareness among people about benefits offered by human cytomegalovirus 65 kDa phosphoprotein therapy. This has led to increased adoption of this therapy across the globe, thereby propelling growth of the global market for human cytomegalovirus 65 kDa phosphoprotein therapeutics over the forecast period.
- Rising number of clinical trials and research activities on human cytomegalovirus65kDAphosphoprotein: A large numberof clinical trials and research activities are being conducted onhumancytomegalo-v irus65kDAphospho-protein acrossthe globe .Thisis
Scope Of The Report
Report Attributes
Report Details
Report Title
Human cytomegalovirus 65 kDa Phosphoprotein Market Research Report
By Type
HB-101, CyMVectin, ASP-0113, PepVax, Others
By Application
Brain Tumor, Hemotaological Tumor, Kidney Transplant Rejection, Liver Transplant Rejection, Others
By Companies
Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc, Vical Inc, Astellas Pharma Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Human cytomegalovirus 65 kDa Phosphoprotein Market Report Segments:
The global Human cytomegalovirus 65 kDa Phosphoprotein market is segmented on the basis of:
Types
HB-101, CyMVectin, ASP-0113, PepVax, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Brain Tumor, Hemotaological Tumor, Kidney Transplant Rejection, Liver Transplant Rejection, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma Inc
- Hookipa Biotech AG
- Immunomic Therapeutics Inc
- Vakzine Projekt Management GmbH
- Vaximm AG
- VBI Vaccines Inc
- Vical Inc
- Astellas Pharma Inc
Highlights of The Human cytomegalovirus 65 kDa Phosphoprotein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HB-101
- CyMVectin
- ASP-0113
- PepVax
- Others
- By Application:
- Brain Tumor
- Hemotaological Tumor
- Kidney Transplant Rejection
- Liver Transplant Rejection
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human cytomegalovirus 65 kDa Phosphoprotein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human cytomegalovirus 65 kDa Phosphoprotein is a viral protein that is responsible for the virus' ability to attach to and enter cells.
Some of the key players operating in the human cytomegalovirus 65 kda phosphoprotein market are Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc, Vical Inc, Astellas Pharma Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human cytomegalovirus 65 kDa Phosphoprotein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human cytomegalovirus 65 kDa Phosphoprotein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human cytomegalovirus 65 kDa Phosphoprotein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human cytomegalovirus 65 kDa Phosphoprotein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size & Forecast, 2020-2028
4.5.1 Human cytomegalovirus 65 kDa Phosphoprotein Market Size and Y-o-Y Growth
4.5.2 Human cytomegalovirus 65 kDa Phosphoprotein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 HB-101
5.2.2 CyMVectin
5.2.3 ASP-0113
5.2.4 PepVax
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Brain Tumor
6.2.2 Hemotaological Tumor
6.2.3 Kidney Transplant Rejection
6.2.4 Liver Transplant Rejection
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 HB-101
9.6.2 CyMVectin
9.6.3 ASP-0113
9.6.4 PepVax
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Brain Tumor
9.10.2 Hemotaological Tumor
9.10.3 Kidney Transplant Rejection
9.10.4 Liver Transplant Rejection
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 HB-101
10.6.2 CyMVectin
10.6.3 ASP-0113
10.6.4 PepVax
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Brain Tumor
10.10.2 Hemotaological Tumor
10.10.3 Kidney Transplant Rejection
10.10.4 Liver Transplant Rejection
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 HB-101
11.6.2 CyMVectin
11.6.3 ASP-0113
11.6.4 PepVax
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Brain Tumor
11.10.2 Hemotaological Tumor
11.10.3 Kidney Transplant Rejection
11.10.4 Liver Transplant Rejection
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 HB-101
12.6.2 CyMVectin
12.6.3 ASP-0113
12.6.4 PepVax
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Brain Tumor
12.10.2 Hemotaological Tumor
12.10.3 Kidney Transplant Rejection
12.10.4 Liver Transplant Rejection
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 HB-101
13.6.2 CyMVectin
13.6.3 ASP-0113
13.6.4 PepVax
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Brain Tumor
13.10.2 Hemotaological Tumor
13.10.3 Kidney Transplant Rejection
13.10.4 Liver Transplant Rejection
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human cytomegalovirus 65 kDa Phosphoprotein Market: Competitive Dashboard
14.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma Inc
14.3.2 Hookipa Biotech AG
14.3.3 Immunomic Therapeutics Inc
14.3.4 Vakzine Projekt Management GmbH
14.3.5 Vaximm AG
14.3.6 VBI Vaccines Inc
14.3.7 Vical Inc
14.3.8 Astellas Pharma Inc
